<DOC>
	<DOC>NCT00191984</DOC>
	<brief_summary>A non-randomized phase II study to determine the efficacy and safety of the combination of Pemetrexed and Irinotecan every two weeks in metastatic colorectal cancer patients.</brief_summary>
	<brief_title>A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis of metastatic colorectal adenocarcinoma that is not amenable to curative therapy. Patient must have at least one unidimensionally measurable lesion. Prior radiation therapy to less than 25% of bone marrow. Radiation must be completed at least 4 weeks prior to study enrollment. Performance status 0 to 2 Patient must have received 1 prior course of chemotherapy (Folfox regimen) for metastatic disease Treatment with any drug within the last 30 days that has not received regulatory approval. Serious systemic disorder (cardiac or pulmonary disease, active infection) Documented brain metastases not amenable to surgery or unstable after radiation Inability or unwillingness to take folic acid or Vitamin B12 supplementation. Presence of fluid retention that can not be controlled by drainage.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>